226 related articles for article (PubMed ID: 30738661)
1. Cost Effectiveness of Early Treatment with Direct-Acting Antiviral Therapy in Adolescent Patients with Hepatitis C Virus Infection.
Nguyen J; Barritt AS; Jhaveri R
J Pediatr; 2019 Apr; 207():90-96. PubMed ID: 30738661
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia.
Scott N; Iser DM; Thompson AJ; Doyle JS; Hellard ME
J Gastroenterol Hepatol; 2016 Apr; 31(4):872-82. PubMed ID: 26514998
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Chronic Hepatitis C in Young Children Reduces Adverse Outcomes and Is Cost-Effective Compared with Deferring Treatment to Adulthood.
Greenaway E; Haines A; Ling SC; Krahn M
J Pediatr; 2021 Mar; 230():38-45.e2. PubMed ID: 32890583
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection.
Chaillon A; Mehta SR; Hoenigl M; Solomon SS; Vickerman P; Hickman M; Skaathun B; Martin NK
PLoS One; 2019; 14(6):e0217964. PubMed ID: 31170246
[TBL] [Abstract][Full Text] [Related]
5. Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States.
Ahmed A; Gonzalez SA; Cholankeril G; Perumpail RB; McGinnis J; Saab S; Beckerman R; Younossi ZM
Hepatology; 2017 Jul; 66(1):46-56. PubMed ID: 28257591
[TBL] [Abstract][Full Text] [Related]
6. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
7. Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?
Marcellusi A; Viti R; Damele F; Cammà C; Taliani G; Mennini FS
Clin Drug Investig; 2016 Aug; 36(8):661-72. PubMed ID: 27234943
[TBL] [Abstract][Full Text] [Related]
8. Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens.
Eckman MH; Ward JW; Sherman KE
Clin Gastroenterol Hepatol; 2019 Apr; 17(5):930-939.e9. PubMed ID: 30201597
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy.
Ruggeri M; Romano F; Basile M; Coretti S; Rolli FR; Drago C; Cicchetti A
Appl Health Econ Health Policy; 2018 Oct; 16(5):711-722. PubMed ID: 30039348
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C: an economic evaluation of extended treatment with interferon.
Shiell A; Brown S; Farrell GC
Med J Aust; 1999 Aug; 171(4):189-93. PubMed ID: 10494234
[TBL] [Abstract][Full Text] [Related]
12. Economic Evaluation of the Hepatitis C Virus Treatment Extension to Early-Stage Fibrosis Patients: Evidence from the PITER Real-World Cohort.
Ruggeri M; Coretti S; Romano F; Kondili LA; Vella S; Cicchetti A
Value Health; 2018 Jul; 21(7):783-791. PubMed ID: 30005750
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal.
Elbasha EH; Chhatwal J; Ferrante SA; El Khoury AC; Laires PA
Appl Health Econ Health Policy; 2013 Feb; 11(1):65-78. PubMed ID: 23355388
[TBL] [Abstract][Full Text] [Related]
14. Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia.
Visconti AJ; Doyle JS; Weir A; Shiell AM; Hellard ME
J Gastroenterol Hepatol; 2013 Apr; 28(4):707-16. PubMed ID: 23173753
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.
Kim KA; Chung W; Choi HY; Ki M; Jang ES; Jeong SH
Liver Int; 2019 Jan; 39(1):60-69. PubMed ID: 29998565
[TBL] [Abstract][Full Text] [Related]
16. Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India.
Chugh Y; Dhiman RK; Premkumar M; Prinja S; Singh Grover G; Bahuguna P
PLoS One; 2019; 14(8):e0221769. PubMed ID: 31465503
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma.
Salazar J; Saxena V; Kahn JG; Roberts JP; Mehta N; Volk M; Lai JC
Transplantation; 2017 May; 101(5):1001-1008. PubMed ID: 27926593
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of chronic hepatitis C treatment in the prison population in Spain.
Marco A; Domínguez-Hernández R; Casado MA
Rev Esp Sanid Penit; 2020; 22(2):66-74. PubMed ID: 32697276
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection.
Logge C; Vettorazzi E; Fischer L; Nashan B; Sterneck M
Transpl Int; 2013 May; 26(5):527-34. PubMed ID: 23517333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
